Ken Griffin Alaunos Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.43 - $0.65 $454 - $686	1,056 Added 3.01%	36,094 $18,000
Q1 2023 May 15, 2023	SELL	$0.46 - $0.81 $330,551 - $582,058	-718,591 Reduced 95.35%	35,038 $22,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $261.0 $341,333 - $178 Million	682,666 Added 962.0%	753,629 $489,000
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $55,905 - $17.3 Million	53,755 Added 312.38%	70,963 $122,000
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $91,979 - $278,182	-224,341 Reduced 92.88%	17,208 $22,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $3,628 - $6,846	-5,852 Reduced 2.37%	241,549 $158,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $198,913 - $344,904	182,489 Added 281.13%	247,401 $269,000
Q3 2021 Nov 15, 2021	SELL	$1.44 - $2.73 $260,295 - $493,477	-180,761 Reduced 73.58%	64,912 $118,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $128,344 - $179,096	48,800 Added 24.79%	245,673 $648,000
Q4 2020 Feb 16, 2021	SELL	$2.09 - $3.09 $440,168 - $650,775	-210,607 Reduced 51.69%	196,873 $496,000
Q3 2020 Nov 16, 2020	BUY	$2.39 - $3.43 $721,137 - $1.03 Million	301,731 Added 285.33%	407,480 $1.03 Million
Q2 2020 Aug 14, 2020	SELL	$2.2 - $3.71 $134,497 - $226,810	-61,135 Reduced 36.63%	105,749 $347,000
Q1 2020 May 15, 2020	SELL	$1.9 - $4.98 $293,337 - $768,852	-154,388 Reduced 48.06%	166,884 $409,000
Q4 2019 Feb 14, 2020	BUY	$3.95 - $5.35 $1.04 Million - $1.41 Million	264,187 Added 462.8%	321,272 $1.52 Million
Q3 2019 Nov 14, 2019	SELL	$4.13 - $6.94 $379,423 - $637,577	-91,870 Reduced 61.68%	57,085 $244,000
Q2 2019 Aug 14, 2019	BUY	$3.98 - $6.2 $118,233 - $184,183	29,707 Added 24.91%	148,955 $868,000
Q4 2018 Feb 14, 2019	SELL	$1.61 - $3.62 $391,466 - $880,192	-243,147 Reduced 67.09%	119,248 $222,000
Q3 2018 Nov 13, 2018	BUY	$2.26 - $3.27 $76,891 - $111,255	34,023 Added 10.36%	362,395 $0
Q2 2018 Aug 10, 2018	BUY	$3.02 - $4.94 $172,870 - $282,775	57,242 Added 21.11%	328,372 $0
Q1 2018 May 11, 2018	BUY	$3.46 - $5.14 $57,557 - $85,503	16,635 Added 6.54%	271,130 $1.06 Million
Q4 2017 Feb 09, 2018	BUY	$4.0 - $6.54 $311,576 - $509,426	77,894 Added 44.11%	254,495 $1.05 Million
Q3 2017 Nov 09, 2017	BUY	$4.99 - $6.57 $881,238 - $1.16 Million	176,601	176,601 $1.09 Million

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $398M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account